Bitdeer Technologies Group vs Eli Lilly And Co — how do they compare? Bitdeer Technologies Group trades at $9.18 (market cap $2.36B), while Eli Lilly And Co trades at $1,222.18 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 457.6× Bitdeer Technologies Group's market cap, and Eli Lilly And Co pays a 0.57% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.
| BTDR | LLY | |
|---|---|---|
Market Cap | $2.36B | $1.08T |
Sector | Technology | Health |
52-Week High | $25.90 | $1.24K |
52-Week Low | $7.28 | $639.43 |
Enterprise Value | $3.85B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $9.18, up 5.58% today but facing bearish technical signals with 13 of 13 moving averages indicating sell signals. The company reported Q2 2026 revenue growth but missed EPS expectations for the fourth consecutive quarter with a loss of $0.37 per share. Recent developments include a significant $4.7 billion AI data center deal announced August 4, 2026, signaling strategic expansion beyond Bitcoin mining into AI infrastructure.
Despite analyst optimism with 82% buy ratings and a $22.43 consensus price target, fundamental challenges persist including negative net income margin (-28.14%) and cash flow concerns. The stock offers substantial upside potential if AI initiatives succeed but faces execution risk amid volatile cryptocurrency markets and competitive pressures in the infrastructure sector.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Trailing returns across standard periods
Latest headlines on both assets
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →